CVRx Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 200
- Market Cap
- -
- Introduction
CVRx, Inc. engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It operates through the United States, Germany, and Other Countries geographical segments. The company was founded by Robert S. Kieval and Tyler P. Lipschultz in August 2001 and is headquartered in Minneapolis, MN.
CVRx's Barostim Receives Medicare Payment Boost, Enhancing Patient Access
• CVRx's Barostim device, designed to treat heart failure by stimulating baroreceptors, has been assigned a new payment classification by CMS, enhancing its market accessibility.
• The Centers for Medicare and Medicaid Services (CMS) has classified Barostim under New Technology APC 1580, ensuring a payment of approximately $45,000, set to continue in 2025.
• CMS also reassigned Barostim to a higher-paying MS-DRG for inpatient procedures, effective October 1, increasing payment from a previous range of $17,000-$23,000 to $43,000.
• The American Medical Association CPT Editorial Panel approved transitioning Barostim from Category III to Category I CPT codes, expected to be implemented on January 1, 2026.
CVRx's Barostim Device Shows Durable Benefits in Heart Failure Patients Over Two Years
• CVRx reported that its Barostim device provides sustained improvements in heart failure patients over 24 months, enhancing their physical and psychosocial well-being.
• The Barostim device, which uses baroreflex activation therapy, electrically stimulates baroreceptors to restore balance to the autonomic nervous system.
• The study, published in the Journal of the American College of Cardiology: Heart Failure, builds on earlier data demonstrating long-term symptomatic benefits.
• Barostim received FDA approval in 2019 for advanced heart failure and expanded its label in 2023 for broader use in heart failure patients.
© Copyright 2025. All Rights Reserved by MedPath